Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
AssigneeThe General Hospital Corporation
InventorsJose BASELGA, Maurizio SCALTRITI
Life of this patent
Estimating the term…
Abstract
The invention provides combinations comprising GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof and ME-HD7945A. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer (e.g., triple negative breast cancer).
Claims23
A combination of GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof, and MEHD7945A, for the therapeutic treatment of a hyperproliferative disorder.
A combination of GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof and MEHD7945A for therapeutic use for improving the quality of life of a patient having a hyperproliferative disorder.
The combination of GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof, and MEHD7945A, for treating a hyperproliferative disorder.
The combination of GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof, and MEHD7945A, for treating a disease or condition modulated by AKT kinase.
The use of a combination of GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof, and MEHD7945A, in the preparation of a medicament for the treatment of a hyperproliferative disorder in a mammal.
The use of a combination of GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof, and MEHD7945A, in preparation of a medicament for the treatment of a disease or condition modulated by AKT kinase in a mammal.
A kit comprising GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof, MEHD7945A, a container, and a package insert or label indicating the administration GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof, and MEHD7945A, for treating a hyperproliferative disorder.
A product comprising GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof and MEHD7945A as a combined preparation for separate, simultaneous or sequential use in the treatment of a hyperproliferative disorder.
A method for treating a hyperproliferative disorder in a mammal, comprising administering to the mammal a combination of GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof, and MEHD7945A.
A method for treating a disease or condition modulated by AKT kinase in a mammal comprising, administering to the mammal, a combination of GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof, and MEHD7945A.
Dependencies are inferred from the claim text.